Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Ropidoxuridine
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Updated results at 4-years and tumor-immune correlates presented at the 48th European Society for Medical Oncology Congress.
- 06 Sep 2023 Planned End Date changed from 1 Jun 2026 to 30 Jun 2026.